Geoffrey Meacham
Citigroup Inc., Research Division
Good morning. Welcome to the Citi Global Healthcare Conference. Continuing this morning. Next up, we have Gilead Sciences. And with us today, we’re pleased to have Andy Dickinson, CFO. Welcome.
Andrew Dickinson
Chief Financial Officer
Thanks for having us again. Appreciate it.
Geoffrey Meacham
Citigroup Inc., Research Division
Of course. But we start this way. Maybe give a couple of minutes to give some opening remarks, and then we’ll go to some questions.
Andrew Dickinson
Chief Financial Officer
Sure. Yes. Maybe 4 things to highlight as we start. One, we’ve had a terrific 2025 so far. You see that in our third quarter results. We increased our guidance for the year. So we can talk about that specifically, but a great first 3 quarters of the year, carrying a lot of momentum in our business overall.
You see the second thing I would highlight is a really strong durable portfolio, so our base business led by our 2 flagship HIV therapies today, Biktarvy and Descovy are driving significant growth. And then we have a number of launches that are underway and coming. Yeztugo, in particular, a new HIV, which should be a transformational HIV prevention medicine. It’s an every 6-month injection and Livdelzi for primary biliary cholangitis, those launches are off to very strong starts. And then we have a number of launches coming.
The third thing I’d highlight is we have the deepest, broadest, strongest portfolio in Gilead’s history pipeline, I should say, which means that you should see a steady cadence of additional clinical data that can drive additional product
Read the full article here